ZA201001660B - Azacytidine analogues and uses thereof - Google Patents

Azacytidine analogues and uses thereof

Info

Publication number
ZA201001660B
ZA201001660B ZA2010/01660A ZA201001660A ZA201001660B ZA 201001660 B ZA201001660 B ZA 201001660B ZA 2010/01660 A ZA2010/01660 A ZA 2010/01660A ZA 201001660 A ZA201001660 A ZA 201001660A ZA 201001660 B ZA201001660 B ZA 201001660B
Authority
ZA
South Africa
Prior art keywords
azacytidine
analogues
azacytidine analogues
Prior art date
Application number
ZA2010/01660A
Other languages
English (en)
Inventor
James Holland
Lewis Silverman
Marit Liland Sandvold
Ole Henrik Eriksen
Finn Myhren
Original Assignee
Sinai School Medicine
Clavis Pharma Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine, Clavis Pharma Asa filed Critical Sinai School Medicine
Publication of ZA201001660B publication Critical patent/ZA201001660B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA2010/01660A 2007-09-26 2010-03-08 Azacytidine analogues and uses thereof ZA201001660B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077673 WO2009042767A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (1)

Publication Number Publication Date
ZA201001660B true ZA201001660B (en) 2011-05-25

Family

ID=40511851

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/01660A ZA201001660B (en) 2007-09-26 2010-03-08 Azacytidine analogues and uses thereof

Country Status (15)

Country Link
US (2) US8399420B2 (enExample)
EP (2) EP2205073A4 (enExample)
JP (2) JP2010540555A (enExample)
KR (2) KR20100102092A (enExample)
CN (2) CN101877964A (enExample)
AU (2) AU2008304380A1 (enExample)
BR (2) BRPI0817269A2 (enExample)
CA (2) CA2700267A1 (enExample)
IL (1) IL204690A0 (enExample)
MX (2) MX2010003261A (enExample)
NZ (2) NZ583824A (enExample)
RU (1) RU2488591C2 (enExample)
UA (2) UA99308C2 (enExample)
WO (2) WO2009042767A1 (enExample)
ZA (1) ZA201001660B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
WO2009042767A1 (en) 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
EP2817029B1 (en) 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
WO2017096357A1 (en) 2015-12-03 2017-06-08 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
ES2963046T3 (es) 2017-03-20 2024-03-25 Vaccinex Inc Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (enExample) 1963-12-22
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) * 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4981613A (en) 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
IE980216A1 (en) 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
WO1992015113A1 (en) * 1991-02-19 1992-09-03 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
WO1993004064A1 (en) * 1991-08-14 1993-03-04 Procter & Gamble Pharmaceuticals, Inc. Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
BR9610070A (pt) * 1995-08-08 1999-07-27 Univ Jefferson Sequência de ácido nucleico polipetídeos compostos antifibrótico e processo para tratar distúrbios ou doenças relacionadas com fibrose para usar a sequência de dna e para produzir c-proteinase recombinante
WO1997009878A1 (en) 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
CA2278056C (en) * 1997-01-24 2006-12-12 Norsk Hydro Asa Gemcitabine derivatives
CN1292073C (zh) * 1997-06-03 2006-12-27 森庸厚 天然抗肿瘤性或抗病毒性物质及其用途
EP1042341A1 (en) 1997-11-25 2000-10-11 Protarga Inc. Nucleoside analog compositions and uses thereof
KR20010082515A (ko) 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
WO2000076979A1 (de) 1999-06-09 2000-12-21 Bayer Aktiengesellschaft Pyridincarboxamide und ihre verwendung als pflanzenschutzmittel
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
BR0014859A (pt) * 1999-10-15 2002-07-16 Hoffmann La Roche Derivados de benzodiazepina
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
CN1615314A (zh) 2001-11-21 2005-05-11 海德堡医药有限责任公司 用作抗肿瘤药的核苷的磷脂衍生物
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2499036A1 (en) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1694642A4 (en) 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc MUTAGENIC HETEROCYCLES
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
JP2007520527A (ja) 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007035783A2 (en) * 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
WO2009042767A1 (en) 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof

Also Published As

Publication number Publication date
CA2700207A1 (en) 2009-04-02
AU2008304380A1 (en) 2009-04-02
UA99308C2 (ru) 2012-08-10
JP2010540556A (ja) 2010-12-24
NZ583824A (en) 2012-06-29
IL204690A0 (en) 2010-11-30
AU2008304381A1 (en) 2009-04-02
US8399420B2 (en) 2013-03-19
BRPI0817234A2 (pt) 2014-09-30
CN101815437A (zh) 2010-08-25
CA2700267A1 (en) 2009-04-02
MX2010003261A (es) 2010-08-18
BRPI0817269A2 (pt) 2014-10-07
EP2197274A4 (en) 2013-03-06
NZ583923A (en) 2012-05-25
EP2205073A1 (en) 2010-07-14
WO2009042766A1 (en) 2009-04-02
UA99836C2 (en) 2012-10-10
KR20100102092A (ko) 2010-09-20
WO2009042767A1 (en) 2009-04-02
CN101877964A (zh) 2010-11-03
RU2488591C2 (ru) 2013-07-27
US20090209477A1 (en) 2009-08-20
WO2009042766A9 (en) 2009-05-28
US20090209482A1 (en) 2009-08-20
RU2010116274A (ru) 2011-11-10
MX2010003002A (es) 2010-07-05
RU2010116154A (ru) 2011-11-10
KR20100072230A (ko) 2010-06-30
US8158605B2 (en) 2012-04-17
EP2205073A4 (en) 2013-03-06
EP2197274A1 (en) 2010-06-23
JP2010540555A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
IL204690A0 (en) Azacytidine analogues and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
IL202699A0 (en) Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
LT2064327T (lt) Dbait ir jų panaudojimas
LT2318366T (lt) Psma surišantys agentai ir jų panaudojimas
IL211742A0 (en) Frizzled-binding agents and uses thereof
IL194751A0 (en) Drugs and uses
GB2443336B (en) Spiruchostatin analogues and their medicinal use
ZA200903906B (en) Carboranylporphyrins and uses thereof
GB0715428D0 (en) Compositions and uses thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0707069D0 (en) Methods and uses
HK1145418A (en) Azacytidine analogues and uses thereof
PL2227486T3 (pl) Analogi peptydowe i ich koniugaty
GB0610059D0 (en) Uses and methods
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB2444960B (en) Combined pseudoscope and hyperscope
GB0724878D0 (en) Peptide analogues and conjugates thereof
GB0621665D0 (en) Blogmail and podmail
GB0711398D0 (en) Substituted organpolysiloxanes and uses thereof